H. Lundbeck (LUN) Investor update summary
Event summary combining transcript, slides, and related documents.
Investor update summary
7 Sep, 2026Strategic positioning and market opportunity
Focused exclusively on neuroscience, addressing a $160bn market potential by 2030 with a mission to advance brain health and transform lives.
Neuroscience is among the fastest growing areas in medicine, with a 10% CAGR and significant unmet needs across brain disorders.
The pipeline is aligned with high-growth neuro-rare and neuro-specialty segments, expanding faster than psychiatry.
Leadership and transformation
A new, diverse executive leadership team with deep experience in global pharma and biotech is driving transformation and innovation.
The strategy is a self-funded transition through loss of exclusivities, focusing on innovation-led growth and sustainable profitability.
Growth and financial performance
Achieved strong revenue growth, with a 5-8% CAGR and a structural shift toward pipeline-driven growth post-2027.
Strategic brands like Vyepti and Rexulti are driving accelerating revenue, with Vyepti positioned as a leading migraine therapy and Rexulti expanding via new indications.
Disciplined capital reallocation and operational effectiveness have improved profitability, with EBITDA margin rising to over 30% by 2025.
Latest events from H. Lundbeck
- Upgraded guidance and late-stage catalysts support the 2027–2029 scale phase.LUN
Jefferies Global Healthcare Conference - Vyepti-led growth and stronger earnings lifted FY 2026 guidance as leverage fell.LUN
Q3 2026 - Vyepti-led growth lifted 9M results and FY 2026 guidance as leverage fell to 0.7x.LUN
Q3 2026 - Strategic-brand growth and pipeline investment support 2026 growth amid generic headwinds.LUN
Q4 2025 - H1 2026 saw 16% CER revenue growth, strong brand and pipeline momentum, and guidance maintained.LUN
Q2 2026 - H1 2026 revenue up 16% CER, strong cash flow, and robust growth from Vyepti and Rexulti.LUN
Q2 2026 - Bocunebart showed strong efficacy and safety in migraine prevention, advancing to Phase III.LUN
Study update - Q1 2026 saw 21% CER revenue growth, margin expansion, and upgraded full-year guidance.LUN
Q1 2026 - Transformative year with late-stage pipeline advances and disciplined capital allocation.LUN
43rd Annual J.P. Morgan Healthcare Conference